Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 4.84
NAS:UTHR's Cash-to-Debt is ranked lower than
63% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:UTHR: 4.84 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:UTHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: 24.91 Max: 15951.56
Current: 4.84
0.69
15951.56
Equity-to-Asset 0.71
NAS:UTHR's Equity-to-Asset is ranked lower than
51% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:UTHR: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:UTHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.71 Max: 0.97
Current: 0.71
0.37
0.97
Debt-to-Equity 0.12
NAS:UTHR's Debt-to-Equity is ranked higher than
65% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:UTHR: 0.12 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:UTHR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.22 Max: 1.54
Current: 0.12
0
1.54
Debt-to-EBITDA 0.30
NAS:UTHR's Debt-to-EBITDA is ranked higher than
82% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:UTHR: 0.30 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:UTHR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.47  Med: 0.82 Max: 11.27
Current: 0.3
-3.47
11.27
Interest Coverage 110.40
NAS:UTHR's Interest Coverage is ranked lower than
71% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:UTHR: 110.40 )
Ranked among companies with meaningful Interest Coverage only.
NAS:UTHR' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 16.2 Max: 272.23
Current: 110.4
2.02
272.23
Piotroski F-Score: 5
Altman Z-Score: 6.85
Beneish M-Score: -2.72
WACC vs ROIC
9.33%
50.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 50.92
NAS:UTHR's Operating Margin % is ranked higher than
97% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:UTHR: 50.92 )
Ranked among companies with meaningful Operating Margin % only.
NAS:UTHR' s Operating Margin % Range Over the Past 10 Years
Min: -29.15  Med: 35.36 Max: 66.41
Current: 50.92
-29.15
66.41
Net Margin % 30.50
NAS:UTHR's Net Margin % is ranked higher than
91% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:UTHR: 30.50 )
Ranked among companies with meaningful Net Margin % only.
NAS:UTHR' s Net Margin % Range Over the Past 10 Years
Min: -17.52  Med: 22.13 Max: 44.64
Current: 30.5
-17.52
44.64
ROE % 26.52
NAS:UTHR's ROE % is ranked higher than
93% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:UTHR: 26.52 )
Ranked among companies with meaningful ROE % only.
NAS:UTHR' s ROE % Range Over the Past 10 Years
Min: -11.59  Med: 19.34 Max: 46.03
Current: 26.52
-11.59
46.03
ROA % 19.92
NAS:UTHR's ROA % is ranked higher than
95% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:UTHR: 19.92 )
Ranked among companies with meaningful ROA % only.
NAS:UTHR' s ROA % Range Over the Past 10 Years
Min: -6.75  Med: 12.09 Max: 32.03
Current: 19.92
-6.75
32.03
ROC (Joel Greenblatt) % 156.83
NAS:UTHR's ROC (Joel Greenblatt) % is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:UTHR: 156.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:UTHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -43.1  Med: 79.54 Max: 215.37
Current: 156.83
-43.1
215.37
3-Year Revenue Growth Rate 17.60
NAS:UTHR's 3-Year Revenue Growth Rate is ranked higher than
70% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:UTHR: 17.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:UTHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 17.6  Med: 37.8 Max: 260.9
Current: 17.6
17.6
260.9
3-Year EBITDA Growth Rate 56.00
NAS:UTHR's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:UTHR: 56.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:UTHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56.2  Med: 22.7 Max: 128
Current: 56
-56.2
128
3-Year EPS without NRI Growth Rate 66.90
NAS:UTHR's 3-Year EPS without NRI Growth Rate is ranked higher than
93% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:UTHR: 66.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:UTHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.7  Med: 19.7 Max: 153.6
Current: 66.9
-50.7
153.6
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:UTHR's 30-Y Financials

Financials (Next Earnings Date: 2018-02-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

UTHR Guru Trades in Q4 2016

Jim Simons 421,200 sh (+7.97%)
Lee Ainslie 26,210 sh (+1.16%)
Ken Fisher 3,124 sh (unchged)
Joel Greenblatt 166,025 sh (-47.69%)
Ray Dalio 43,905 sh (-61.42%)
Paul Tudor Jones 3,534 sh (-65.02%)
David Dreman 146 sh (-94.53%)
» More
Q1 2017

UTHR Guru Trades in Q1 2017

Jeremy Grantham 1,500 sh (New)
John Hussman 25,500 sh (New)
Caxton Associates 2,200 sh (New)
Ray Dalio 58,092 sh (+32.31%)
Joel Greenblatt 209,140 sh (+25.97%)
Jim Simons 506,200 sh (+20.18%)
Paul Tudor Jones 3,700 sh (+4.70%)
Ken Fisher 3,124 sh (unchged)
David Dreman Sold Out
Lee Ainslie 19,440 sh (-25.83%)
» More
Q2 2017

UTHR Guru Trades in Q2 2017

David Dreman 3,466 sh (New)
Jim Simons 837,600 sh (+65.47%)
Jeremy Grantham 2,400 sh (+60.00%)
Ray Dalio 73,968 sh (+27.33%)
Caxton Associates 2,800 sh (+27.27%)
Ken Fisher 3,169 sh (+1.44%)
Paul Tudor Jones Sold Out
John Hussman 25,250 sh (-0.98%)
Lee Ainslie 18,720 sh (-3.70%)
Joel Greenblatt 193,990 sh (-7.24%)
» More
Q3 2017

UTHR Guru Trades in Q3 2017

Paul Tudor Jones 7,777 sh (New)
Jim Simons 1,273,000 sh (+51.98%)
Ray Dalio 92,770 sh (+25.42%)
Jeremy Grantham 2,400 sh (unchged)
David Dreman 3,466 sh (unchged)
Caxton Associates Sold Out
Lee Ainslie Sold Out
John Hussman 25,000 sh (-0.99%)
Joel Greenblatt 181,185 sh (-6.60%)
Ken Fisher 2,649 sh (-16.41%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Reduce -6.60%0.02%$114.6 - $136.81 $ 125.41-2%181,185
Ken Fisher 2017-09-30 Reduce -16.41%$114.6 - $136.81 $ 125.41-2%2,649
Joel Greenblatt 2017-06-30 Reduce -7.24%0.03%$118.34 - $135.38 $ 125.410%193,990
David Dreman 2017-06-30 New Buy0.25%$118.34 - $135.38 $ 125.410%3,466
Ken Fisher 2017-06-30 Add 1.44%$118.34 - $135.38 $ 125.410%3,169
Joel Greenblatt 2017-03-31 Add 25.97%0.07%$135.38 - $168.42 $ 125.41-17%209,140
David Dreman 2017-03-31 Sold Out 0.01%$135.38 - $168.42 $ 125.41-17%0
Joel Greenblatt 2016-12-31 Reduce -47.69%0.23%$111.68 - $145.38 $ 125.41-2%166,025
David Dreman 2016-12-31 Reduce -94.53%0.18%$111.68 - $145.38 $ 125.41-2%146
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XAMS:GLPG, NAS:NBIX, NAS:JUNO, XKRX:128940, NAS:TECH, NAS:PBYI, HKSE:01530, SZSE:000661, NAS:BIVV, NAS:ACAD, NAS:TSRO, SZSE:002007, OSTO:SOBI, NAS:FGEN, NAS:BLUE, HKSE:02269, LSE:BTG, NAS:CLVS, SHSE:600201, TSE:4587 » details
Traded in other countries:UTH.Germany,
Headquarter Location:USA
United Therapeutics Corp is engaged in the healthcare sector. Its core offering includes pharmaceutical products to address unmet medical needs of patients.

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The firm is a market leader in two of the three primary drugs classes used to treat PAH. Nearly all of its sales are generated within the U.S. United also markets a pediatric oncology drug.

Ratios

vs
industry
vs
history
PE Ratio 10.97
UTHR's PE Ratio is ranked higher than
83% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. UTHR: 10.97 )
Ranked among companies with meaningful PE Ratio only.
UTHR' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 18.93 Max: 171.34
Current: 10.97
4.95
171.34
Forward PE Ratio 10.65
UTHR's Forward PE Ratio is ranked higher than
88% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. UTHR: 10.65 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.97
UTHR's PE Ratio without NRI is ranked higher than
85% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. UTHR: 10.97 )
Ranked among companies with meaningful PE Ratio without NRI only.
UTHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.95  Med: 18.94 Max: 171.34
Current: 10.97
4.95
171.34
Price-to-Owner-Earnings 15.40
UTHR's Price-to-Owner-Earnings is ranked higher than
70% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. UTHR: 15.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
UTHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.08  Med: 35.37 Max: 577.3
Current: 15.4
5.08
577.3
PB Ratio 2.61
UTHR's PB Ratio is ranked higher than
66% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. UTHR: 2.61 )
Ranked among companies with meaningful PB Ratio only.
UTHR' s PB Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.68 Max: 10.39
Current: 2.61
2.01
10.39
PS Ratio 3.36
UTHR's PS Ratio is ranked higher than
79% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. UTHR: 3.36 )
Ranked among companies with meaningful PS Ratio only.
UTHR' s PS Ratio Range Over the Past 10 Years
Min: 2.83  Med: 5.31 Max: 11.47
Current: 3.36
2.83
11.47
Price-to-Free-Cash-Flow 8.68
UTHR's Price-to-Free-Cash-Flow is ranked higher than
88% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. UTHR: 8.68 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
UTHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.84  Med: 18.31 Max: 644.84
Current: 8.68
7.84
644.84
Price-to-Operating-Cash-Flow 7.82
UTHR's Price-to-Operating-Cash-Flow is ranked higher than
90% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. UTHR: 7.82 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
UTHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.13  Med: 16.39 Max: 46
Current: 7.82
7.13
46
EV-to-EBIT 5.53
UTHR's EV-to-EBIT is ranked higher than
85% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. UTHR: 5.53 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.2  Med: 9.6 Max: 122
Current: 5.53
-31.2
122
EV-to-EBITDA 5.30
UTHR's EV-to-EBITDA is ranked higher than
85% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. UTHR: 5.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
UTHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7  Med: 9 Max: 103.2
Current: 5.3
-33.7
103.2
EV-to-Revenue 2.66
UTHR's EV-to-Revenue is ranked higher than
86% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. UTHR: 2.66 )
Ranked among companies with meaningful EV-to-Revenue only.
UTHR' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.4  Med: 4.8 Max: 11.8
Current: 2.66
2.4
11.8
PEG Ratio 0.32
UTHR's PEG Ratio is ranked higher than
94% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. UTHR: 0.32 )
Ranked among companies with meaningful PEG Ratio only.
UTHR' s PEG Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.39 Max: 2.42
Current: 0.32
0.16
2.42
Shiller PE Ratio 21.17
UTHR's Shiller PE Ratio is ranked higher than
86% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. UTHR: 21.17 )
Ranked among companies with meaningful Shiller PE Ratio only.
UTHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.29  Med: 45.31 Max: 679.13
Current: 21.17
19.29
679.13
Current Ratio 2.08
UTHR's Current Ratio is ranked lower than
76% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. UTHR: 2.08 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.97 Max: 64.22
Current: 2.08
0.96
64.22
Quick Ratio 1.93
UTHR's Quick Ratio is ranked lower than
74% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. UTHR: 1.93 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 4.74 Max: 64.22
Current: 1.93
0.9
64.22
Days Inventory 475.09
UTHR's Days Inventory is ranked lower than
92% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. UTHR: 475.09 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s Days Inventory Range Over the Past 10 Years
Min: 118.32  Med: 167.09 Max: 475.09
Current: 475.09
118.32
475.09
Days Sales Outstanding 55.05
UTHR's Days Sales Outstanding is ranked higher than
55% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. UTHR: 55.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.71  Med: 45.68 Max: 55.05
Current: 55.05
36.71
55.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.20
UTHR's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. UTHR: 5.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UTHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.9  Med: -0.85 Max: 5.2
Current: 5.2
-9.9
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 15.72
UTHR's Price-to-Net-Cash is ranked lower than
81% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. UTHR: 15.72 )
Ranked among companies with meaningful Price-to-Net-Cash only.
UTHR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.51  Med: 10.4 Max: 160.03
Current: 15.72
1.51
160.03
Price-to-Net-Current-Asset-Value 7.01
UTHR's Price-to-Net-Current-Asset-Value is ranked lower than
54% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. UTHR: 7.01 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
UTHR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.46  Med: 10.04 Max: 5533
Current: 7.01
1.46
5533
Price-to-Tangible-Book 2.68
UTHR's Price-to-Tangible-Book is ranked higher than
72% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. UTHR: 2.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
UTHR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 3.6 Max: 18.16
Current: 2.68
1.16
18.16
Price-to-Intrinsic-Value-Projected-FCF 0.73
UTHR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
91% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. UTHR: 0.73 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
UTHR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.69  Med: 2.03 Max: 232.67
Current: 0.73
0.69
232.67
Price-to-Median-PS-Value 0.64
UTHR's Price-to-Median-PS-Value is ranked higher than
74% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. UTHR: 0.64 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
UTHR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.45 Max: 299.08
Current: 0.64
0.59
299.08
Price-to-Peter-Lynch-Fair-Value 0.44
UTHR's Price-to-Peter-Lynch-Fair-Value is ranked higher than
95% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. UTHR: 0.44 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
UTHR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.21  Med: 0.97 Max: 5.82
Current: 0.44
0.21
5.82
Price-to-Graham-Number 1.14
UTHR's Price-to-Graham-Number is ranked higher than
80% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. UTHR: 1.14 )
Ranked among companies with meaningful Price-to-Graham-Number only.
UTHR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.77  Med: 2.37 Max: 6.18
Current: 1.14
0.77
6.18
Earnings Yield (Greenblatt) % 18.06
UTHR's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. UTHR: 18.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
UTHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.9  Med: 6.7 Max: 40.2
Current: 18.06
-5.9
40.2
Forward Rate of Return (Yacktman) % 37.48
UTHR's Forward Rate of Return (Yacktman) % is ranked higher than
88% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. UTHR: 37.48 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
UTHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.4  Med: 1.6 Max: 56.9
Current: 37.48
-1.4
56.9

More Statistics

Revenue (TTM) (Mil) $1,669.60
EPS (TTM) $ 11.40
Beta1.16
Short Percentage of Float14.78%
52-Week Range $112.01 - 169.89
Shares Outstanding (Mil)43.21

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1,691 1,439 1,233 1,256
EPS ($) 15.02 11.83 8.92 9.09
EPS without NRI ($) 15.02 11.83 8.92 9.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-10.22%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}